Yes, patients with an eGFR ≥ 45 mL/min/1.73 m² may continue the standard dose, but those with eGFR 30-44 mL/min/1.73 m² require dose adjustment or close monitoring. The prescribing clinician will decide the appropriate regimen based on renal function tests.
Sitagliptin is weight-neutral, while metformin is often associated with modest weight loss. Clinical experience shows that the combination does not typically cause weight gain; some patients even experience slight reductions in body weight.
Yes, but keep the medication in its original packaging with a copy of the prescription. Carry a pharmacist-verified letter if you are traveling to countries with strict drug-import regulations. Store the tablets at room temperature and avoid exposure to extreme heat or humidity.
Co-administration is possible, but it increases the risk of hypoglycaemia. If a sulfonylurea is added, the clinician may lower its dose and advise regular blood-glucose monitoring, especially after meals.
If you miss the evening dose, take it with the next main meal (i.e., the evening if you break your fast). Do not double the dose. Discuss any needed adjustments with your diabetes specialist before Ramadan begins.
Pharmacologically, the active ingredients are identical. The fixed-dose combination reduces pill burden, which can improve adherence. However, dose flexibility is limited; if a clinician wishes to adjust one component without changing the other, separate tablets may be preferred.
Significant reductions in HbA1c are usually observed after 8-12 weeks of consistent therapy, provided diet and lifestyle measures are maintained.
Both sitagliptin and metformin are not prohibited substances under UK Anti-Doping regulations. However, athletes should disclose all medications to their medical support team and retain documentation of the prescription.
The specific excipients are listed in the product’s Summary of Product Characteristics (SPC). Common tablet fillers include lactose, magnesium stearate, and microcrystalline cellulose, but the exact composition should be verified from the official label.
Yes, generic formulations containing sitagliptin and metformin in the same strengths (50 mg/1000 mg) are available once the original product’s patent expires. They are therapeutically equivalent when prescribed by a prescriber.
Istamet is a prescription-only pill that combines two active ingredients-sitagliptin (50 mg) and metformin (1000 mg)-into a single tablet. It belongs to the therapeutic class of diabetes medicines and is used to improve blood-glucose control in adults with type 2 diabetes mellitus (T2DM). In the United Kingdom the product is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is available only with a medical prescription.
Istamet lowers blood glucose through two complementary mechanisms:
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. By blocking the DPP-4 enzyme, it prolongs the activity of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones increase insulin secretion from the pancreas and suppress glucagon release when blood glucose is elevated, helping to bring glucose levels down after meals.
Metformin belongs to the biguanide class. It primarily reduces hepatic glucose production (gluconeogenesis) and improves peripheral insulin sensitivity, allowing muscles and fat tissue to take up glucose more efficiently. Metformin also modestly reduces intestinal absorption of glucose.
Together, the drugs provide both an insulin-dependent (sitagliptin) and an insulin-independent (metformin) reduction in blood-sugar levels, which can lead to better overall glycaemic control than either agent alone.
Istamet is approved in the UK for the treatment of adults with type 2 diabetes mellitus when diet, exercise, and monotherapy with either sitagliptin or metformin alone do not achieve adequate glycaemic control. It is intended for patients who require combined therapy but wish to reduce pill burden by using a fixed-dose combination.
Typical candidates include:
These events are generally mild and resolve without medical intervention. Taking the tablet with food can reduce gastrointestinal discomfort.
If patients are taking over-the-counter supplements or herbal products, they should discuss them with a healthcare professional to avoid unforeseen interactions.
This article provides educational information about Istamet and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
